News
GMAB
51.74
-3.95%
-2.13
Genmab Reports Share Sales by Two Board Members
TipRanks · 13h ago
Genmab Files Articles of Association Dated November 10
TipRanks · 18h ago
Genmab Discloses Executive Bradley Bailey’s Sale of 1,071 Shares
TipRanks · 18h ago
Genmab Reports November 10 Executive Share Sales
TipRanks · 18h ago
Genmab Announces DKK 369.7 Million Share Capital Increase From Employee Warrants
TipRanks · 2d ago
Bicara Therapeutics price target lowered to $37 from $39 at BTIG
TipRanks · 2d ago
ValuEngine Weekly Market Commentary With Outlook For The Remainder Of 2026
Seeking Alpha · 3d ago
Weekly Report: what happened at GMAB last week (1102-1106)?
Weekly Report · 4d ago
Bank of America Securities Sticks to Its Buy Rating for Genmab (GMAB)
TipRanks · 6d ago
Genmab Earnings Call Signals Growth, Pipeline Power and 2027 Potential
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX) and Genmab (GMAB)
TipRanks · 6d ago
Genmab (GMAB) Q3 2026 Earnings Call Transcript
The Motley Fool · 6d ago
Truist Financial Sticks to Its Buy Rating for Genmab (GMAB)
TipRanks · 6d ago
Morgan Stanley Keeps Their Hold Rating on Genmab (GMAB)
TipRanks · 6d ago
Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)
TipRanks · 11/06 07:16
Genmab Q3 EPS $5.51 Beats $3.59 Estimate, Sales $1.187B Miss $1.194B Estimate
Benzinga · 11/05 21:01
Genmab Affirms FY2026 Sales Guidance of $4.325B-$4.525B vs $4.472B Est
Benzinga · 11/05 20:53
Genmab Q3 2026 Earnings Call Transcript
Benzinga · 11/05 18:27
Genmab Reports 22% Revenue Growth as Phase 3 Results Strengthen Oncology Portfolio
TipRanks · 11/05 16:33
Genmab reports Q3 results
Seeking Alpha · 11/05 16:17
More
Webull provides a variety of real-time GMAB stock news. You can receive the latest news about Genmab through multiple platforms. This information may help you make smarter investment decisions.
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.